WHO-in Covaxin chungchangah sawifiahna dang la duh

World Health Organisation-a technical advisory group chuan Thawhlehni khan Bharat Biotech Covid-19 vaccine siam, Covaxin chu Emergency Use Listing-a telh tura dil chungchangah sawifiahna dang pe leh turin a ti.

Technical advisory group-te hi Covaxin chungchangah thutlukna siam turin November 3 hian an inhmu khawm leh dawn a ni.

Hyderabad-a hmun­pui nei Bharat Biotech hian April 19 khan WHO hnenah an vaccine siam hi Emergency Use Listing (EUL) pawmpuina an neih theihnan EOI (Expression of Interest) an thehlut tawh a ni. Hun rei tak ngaihtuah a nih hnuin technical advisory group hi Thawhlehni khan an dilna hi ngaihtuah lehin Covaxin data te an ennawn leh.

"TAG te chu October 26,2021 khan inhmuin, khawvel huapa hman tura vaccine hi pawm a nih theihna turin a siamchhuaktu lam aṭangin sawifiahna dang duh belh leh a ni," tiin WHO chuan a sawi. TAG hian vaccine siamchhuaktute aṭangin tunkar chhungin sawifiahna hi an dang hman beisei a ni a, November 3 hian final risk-benefit assessment nei turin an inhmukhawm leh dawn a ni.

Technical Advisory Group for Emergency Use Listing (TAG-EUL) hi independent advisory group niin, Covid-19 vaccine te chu EUL kalphung hnuaia emergency-a hman atan a pawm tlak leh tlak loh chungchanga WHO hnena thurawn pe ṭhin tu an ni.

Covaxin hian Covid-19 hri natna langchhuak, symptomatic lakah 77.8% in hna a thawk thei a, hri inkaichhawn awlsam tak Delta variant lakah 65.2% in a veng thei niin company chuan a sawi. June khan company chuan Covaxin hnathawh dan enfiahna, Phase 3 trial an zo tawh tih an sawi.

WHO hian tun thleng hian Covid-19 vaccine Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson & Johnson-Janssen, Moderna, leh Sinopharm te chu emergency-a hman atan a pawmpui tawh. Covaxin leh Covishield-te chu India rama Covid vaccine hman tlanglawn ber pahnih an ni.